Monoclonal antibodies and use thereof
An antibody capable of recognizing amyloid β while not recognizing amyloid β precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid β while not recognizing amyloid β precursor proteins, an amyloid β assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.
1. A monoclonal antibody that recognizes amyloid β that is the monoclonal antibody designated 1A10, 82E1, or a chimeric or humanized form of the antibody designated 1A10 or 82E1.
2. The monoclonal antibody of claim 1 that is the monoclonal antibody designated 1A10 or a chimeric or humanized form thereof.
3. The monoclonal antibody of claim 2 that is the humanized form of the monoclonal antibody designated 1A10.
4. The monoclonal antibody of claim 2 that is the monoclonal antibody designated 1A10.
5. A pharmaceutical composition comprising the monoclonal antibody of claim 2 and one or more pharmaceutically acceptable carriers or additives.
6. The monoclonal antibody of claim 1 that is the monoclonal antibody designated 82E1 or a chimeric or humanized form thereof.
7. The monoclonal antibody of claim 6 that is the humanized form of the monoclonal antibody designated 82E1.
8. The monoclonal antibody of claim 6 that is the monoclonal antibody designated 82E1.
9. A pharmaceutical composition comprising the monoclonal antibody of claim 6 and one or more pharmaceutically acceptable carriers or additives.
10. A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 2 to an individual in need of such treatment.
11. The method of claim 10 wherein said disease is Alzheimer's disease.
12. A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 2 to an individual in need of such inhibition.
13. A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 3 to an individual in need of such treatment.
14. A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 6 to an individual in need of such treatment.
15. The method of claim 14 wherein said disease is Alzheimer's disease.
16. A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 6 to an individual in need of such inhibition.
17. A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 7 to an individual in need of such treatment.